Opens in a new tab

Dr. Zhang Qingjiong

Chinese name: 张清炯
Professor, Chief Physician, Doctoral Supervisor . Pediatric & Genetic Eye Diseases
Dr. Zhang Qingjiong is a professor at the Zhongshan Ophthalmic Center, Sun Yat-sen University, and Executive Deputy Director of the State Key Laboratory of Ophthalmology. A recipient of the National Science Fund for Distinguished Young Scholars, he studies the genetic causes of paediatric and inherited eye disease and manages children with complex genetic visual disorders.

Private & confidential

No obligation

Coordinated end-to-end by Orisene

35+ years
Ophthalmic genetics clinical research and practice
336 papers (237 SCI-indexed, h-index 46)
Peer-reviewed publications
one of the world's largest collections
Ocular genetic disease pedigree resource bank

  • The Physician

About Dr. Zhang Qingjiong

Dr. Zhang Qingjiong is a professor and doctoral supervisor at the Zhongshan Ophthalmic Center, Sun Yat-sen University, and Executive Deputy Director of the State Key Laboratory of Ophthalmology. A recipient of the National Science Fund for Distinguished Young Scholars, he has devoted his career to the genetic basis of paediatric and inherited eye disease. His team has identified numerous genes and mutations underlying congenital cataract, high myopia, retinal dystrophy and cone disorders, and built one of China's largest resources for genetic eye disease. He has published more than 200 papers in international journals and serves in medical genetics societies at home and abroad.
1、Professor at the Zhongshan Ophthalmic Center, Sun Yat-sen University
2、Executive Deputy Director of the State Key Laboratory of Ophthalmology
3、Recipient of the National Science Fund for Distinguished Young Scholars
4、Former Vice Director of the Zhongshan Ophthalmic Center and Director of the Eye Institute
5、Standing member of the Chinese Society of Medical Genetics and chair of its Guangdong branch
6、Honorary Fellow of the Association for Research in Vision and Ophthalmology (FARVO)

Dr. Zhang Qingjiong ’s Three Key Areas of Expertise

Three areas of focused expertise, each supported by a deep subspecialty team, high case volumes and an English-speaking care pathway coordinated by Orisene.

Inherited retinal disease

He diagnoses and manages inherited retinal dystrophies and cone-rod disorders, using genetic testing to identify causative mutations, carefully counsel and support families and guide long-term surveillance and emerging future gene-based treatments and management for these progressive blinding conditions in children and adults.

Congenital and early-onset high myopia

He investigates the genetic causes of congenital and early-onset high myopia, identifying genes such as ARR3, and provides accurate genetic diagnosis, risk assessment, family counselling and family support to guide early intervention and visual care for affected children and their relatives.

Paediatric genetic eye disease

He evaluates children with congenital cataract, nystagmus, amblyopia and syndromic eye disorders, carefully integrating detailed clinical examination with genetic testing to reach a precise diagnosis and coordinate individualised multidisciplinary care, support services, genetic counselling and long-term follow-up for affected families.

More: congenital cataract——genetic diagnosis; nystagmus——evaluation; amblyopia——management; retinal dystrophy——genetic testing; genetic counselling——family support

  • Clinical Practice & Publications

Selected cases, research & publications

Representative work drawn from documented clinical treatments, publicly indexed literature, and hospital project records, reflecting the depth of this physician's hands-on expertise and academic rigor.
1. Identification of TRIM49 as a Novel Causative Gene for Autosomal Recessive Retinitis Pigmentosa
Using whole-exome sequencing of unrelated retinitis pigmentosa families against 7,283 in-house controls, this study identified biallelic TRIM49 variants as a novel cause of autosomal recessive retinitis pigmentosa. Functional analyses showed TRIM49 regulates ULK1-mediated autophagy and photoreceptor phagocytosis in retinal pigment epithelium, offering a new therapeutic target for inherited retinal disease and retinal degeneration.
2. X-Linked Heterozygous Mutations in ARR3 Cause Female-Limited Early-Onset High Myopia
This study first linked heterozygous ARR3 mutations to early-onset high myopia restricted to females, defining Myopia-26 with X-linked female-limited inheritance. Combining linkage analysis and whole-exome sequencing across three families, it revealed a novel hereditary pattern, providing a molecular basis for genetic diagnosis, genetic counseling, and early myopia management in affected families.
3. Genetic and Clinical Landscape of ARR3-Associated MYP26 in Early-Onset High Myopia
In 928 Chinese families with early-onset high myopia, ARR3 emerged as the most frequently implicated Mendelian gene. Twenty-four pathogenic variants caused mild cone impairment and slowly progressive pathologic myopia under X-linked female-limited inheritance. The findings guide molecular diagnosis, risk prediction, and clinical monitoring for inherited high myopia and myopic retinopathy.
4. An Ophthalmic Targeted Exome Sequencing Panel for Precision Diagnosis of Hereditary Eye Diseases
This next-generation sequencing panel covers 126 genes, achieving a 52% diagnostic yield across 568 probands with hereditary eye diseases, including inherited retinal degeneration and retinal dystrophy. It enables rapid, affordable clinical genetic testing with a 30-day turnaround, improving genetic counseling, prognosis, and access to gene-specific therapy for families.
5. Bietti Crystalline Corneoretinal Dystrophy Caused by Mutations in the Novel Gene CYP4V2
This landmark genetic study identified CYP4V2 mutations as the cause of autosomal recessive Bietti crystalline corneoretinal dystrophy in most tested patients, characterized by retinal crystals, progressive night blindness, and visual field constriction. The discovery established the molecular basis for genetic diagnosis and for emerging CYP4V2 gene therapy in inherited retinal disease.
6. Variant and Clinical Landscape of Leber Hereditary Optic Neuropathy in 1516 Families
Analyzing 1540 patients from 1516 families, this study defined the mtDNA variant spectrum and prognostic features of Leber hereditary optic neuropathy. A novel optic disc progression grade predicted blindness risk, showing that later onset and higher grade worsen prognosis. These insights guide genetic testing, counseling, and emerging gene therapy for inherited optic neuropathy.
  • Affiliated Hospital

Where Dr. Zhang Qingjiong practices

Guangzhou

Zhongshan Ophthalmic Center, Sun Yat-sen University

Chinese name: 中山大学中山眼科中心
Zhongshan Ophthalmic Center, China's largest public eye hospital and the country's only WHO Collaborating Centre for Eye Health and Vision, performs 100,000+ surgeries a year with a 93.83% day-surgery rate and serves 1.4 million annual outpatient visits.
Since 1835
191 years of eye care
100,000+
Annual eye surgeries
1.4 million
Annual outpatient visits
93.83%
Annual eye surgeries
View Hospital Profile
Appointments with this physician are booked through official hospital channels only, coordinated end-to-end by Orisene.
  • WHY INTERNATIONAL PATIENTS CHOOSE CHINA

Why patients travel to China for treatment

Six reasons international patients now put China on their shortlist — from internationally aligned clinical capability to the policy channels that make treatment here genuinely reachable.

Clinical capability at international standard

Chinese hospitals deliver internationally aligned protocols, performing vast volumes of advanced robotic, minimally invasive, and complex transplant surgeries annually. This massive clinical data and highly specialized workforce ensure world-class outcomes, even for rare and complex cases.

Diagnostics and treatment in days, not months

A full medical workup that typically means months of waiting elsewhere is completed in China within 48–72 hours. Imaging, labs, and multidisciplinary consultations are integrated into a single visit, allowing treatment to commence immediately.

Transparent, itemised pricing

Chinese healthcare offers legally binding, itemised cost estimates before treatment begins, eliminating hidden fees or surprise billing. Due to national centralized procurement, total expenses remain 40–70% lower than comparable care in Western Europe or North America.

Policy channels that open the door

China facilitates access through 240-hour visa-free transit and dedicated medical visa routes. Policies like the Greater Bay Area drug pathway and Boao Lecheng’s pilot zone allow designated hospitals to administer innovative therapies not yet globally approved.
  • International Patient Guide

Consulting this physician, step by step

From the first message to the follow-up after you fly home, one coordinator, no paperwork on your side.
01
Day 0
  • Share your story
    A private consultation with an Orisene advisor, by message, phone or video. Send medical records in any language. Nothing is shared with the hospital yet.
02
Days 1–3
  • Records review & matching
    Orisene translates and presents your case to the right specialist. The hospital returns a tailored care plan, with costs itemised once that plan is confirmed.
03
Days 3–7
  • Your consultation
    Appointments are booked through official hospital channels only. Your navigator accompanies every visit with real-time interpretation, so you can focus on one thing: being cared for.
04
After you fly home
  • Reports & follow-up
    Translated reports and prescriptions delivered within days, remote follow-up coordination with your physicians at home, and a standing line to your navigator.
Orisene offers English and multilingual services, a professional medical interpreter at every consultation, plus translation of your records, reports and prescriptions.

Ready to plan your consultation with Dr. Zhang Qingjiong?

Send your records in any language. An Orisene advisor will reply within 2 hours, present your case to the right specialist, and return a tailored care plan with itemised costs, before anything is booked. Simple. Private. Efficient.
Contact

Confidential, permanently

Independent — no hospital commission

We never handle medical fees

Information Sources

This physician profile is compiled by the Orisene team from publicly available online sources and verified at the time of publication. Details may change, and physician availability is confirmed at the time of booking.

Disclaimer: This information is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal medical guidance.

Mention of any specific product, brand, or manufacturer is for informational purposes only and does not constitute an endorsement or recommendation by Dr. Zhang Qingjiong.